ArticleInternational journal of rheumatology2012
Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?
Article in International journal of rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.Clinical pharmacokinetics · 2014Trial
- Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.BioMed research international · 2014Trial
- Long-term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate-polyglutamate 3.Fundamental & clinical pharmacology · 2025Article
- Drug-microbiota interactions: an emerging priority for precision medicine.Signal transduction and targeted therapy · 2023Review
- Methotrexate Polyglutamates Analysis by Chromatography Methods in Biological Matrices: A Review.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021Review
- The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Drug Response Diversity: A Hidden Bacterium?Journal of personalized medicine · 2021Review
- Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation.Cell host & microbe · 2021Article
- Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction.Journal of inflammation research · 2021Review
- Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.Frontiers in immunology · 2021Review
- The advances of methotrexate resistance in rheumatoid arthritis.Inflammopharmacology · 2020Review
- Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.Nature reviews. Rheumatology · 2020Review
- Association of genesLeukemia research reports · 2020Article
- Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis.Rheumatology international · 2019Article
- MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.Clinical rheumatology · 2019Article
- Systematic review and meta-analysis of the efficacy and safety of Biqi capsule in rheumatoid arthritis patients.Experimental and therapeutic medicine · 2018Article
- No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Article
- Exosomal amyloid A and lymphatic vessel endothelial hyaluronic acid receptor-1 proteins are associated with disease activity in rheumatoid arthritis.Arthritis research & therapy · 2017Article
- Simplification of a pharmacokinetic model for red blood cell methotrexate disposition.European journal of clinical pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, despite its efficacy and affordability, additional DMARDs or biologic agents are often required in order to achieve the recommended goals of low disease activity or remission. Although well tolerated by most, some patients develop important side effects such as cytopenias, gastrointestinal adverse events (stomatitis, nausea), or abnormal liver function tests, which may limit its use and may result in additional health care costs. Given the clinical implications of widespread use of MTX in RA, various studies have evaluated the role of potential biomarkers in predicting treatment effectiveness of MTX. These biomarkers include RBC MTX polyglutamate (PG) levels; genetic variation in genes from relevant biological and metabolic pathways; gene expression profiles; serum proteins. This paper provides an update on the current data regarding biomarkers of treatment response to MTX.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.